With the use of the ASOs to target the SCN1A NAT, one study was effectively able to rescue the sense SCN1A gene expression, ameliorate neuronal excitability and seizures in a mouse model of DS—an effect that almost entirely recapitulates the rescued phenotypes observed via CRISPRa treatment [74, 75]. This evidence concerns the gene SCN1A and Dravet syndrome.